Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

ClinicalTrials.gov ID: NCT00002945

Public ClinicalTrials.gov record NCT00002945. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia

Study identification

NCT ID
NCT00002945
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Roswell Park Cancer Institute
Other
Enrollment
61 participants

Conditions and interventions

Conditions

Interventions

  • aldesleukin Biological
  • filgrastim Biological
  • cyclophosphamide Drug
  • cytarabine Drug
  • etoposide Drug
  • idarubicin Drug
  • melphalan Drug
  • peripheral blood stem cell transplantation Procedure
  • radiation therapy Radiation

Biological · Drug · Procedure + 1 more

Eligibility (public fields only)

Age range
25 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 1996
Primary completion
Jul 31, 2001
Completion
Jul 31, 2011
Last update posted
Apr 12, 2012

1996 – 2011

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Roswell Park Cancer Institute Buffalo New York 14263-0001

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00002945, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2012 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00002945 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →